TORONTO, ONTARIO--(Marketwired - April 2, 2014) - Solutions4CO2 Inc. ("S4CO2" or the "Company") (TSX VENTURE:SFC) is pleased to announce an investor call to review the recently press released 2013 YE Financial Results and MD&A on Wednesday April 16th, 2014 at 10:00 am EDT. Please find conference call information below. In addition, the Company will present its plan to complete the repositioning of the Company as a producer and marketer of natural specialty oils to the health and wellness industry. Proper use of these specialty oils in end products for human consumption has been clinically proven to improve heart, eye, brain and joint health.
As part of this repositioning strategy, the Company will seek shareholder approval at its upcoming Annual Shareholders Meeting scheduled for May 28, 2014, to change its name from Solutions4CO2 Inc. to Blue Ocean NutraSciences.
Solutions4CO2 Inc. has developed a number of natural specialty oil product platforms and has plans to begin manufacturing and selling these natural specialty oils beginning in Q2, 2014.
Our first natural specialty oil product is a natural, high phospholipid omega 3 and astaxanthin rich oil derived from shrimp by-products supplied through our previously press released joint venture with a major Canadian shrimp processor. The higher phospholipid and much higher astaxanthin profile of our natural shrimp oil is superior to existing krill oil profiles in the marketplace.
Astaxanthin is the world's most powerful known anti oxidant. Proper use of astaxanthin products for human consumption has been clinically proven to improve joint, eye, heart and brain health. Industry sources estimate this growing market will reach US$700M by 2016. This market is currently being supplied by higher cost astaxanthin derived from micro algae.
Other astaxanthin uses include aquaculture fish pigmentation (i.e. salmon and trout), a growing $1 billion annual global market. This market is currently being supplied with a lower cost synthetically manufactured astaxanthin.
Use of Omega 3 products for human consumption has been clinically proven to improve heart and brain health. Over 11,000 health studies have been performed on Omega3 since the early 1970's. The retail global Omega 3 market is estimated to exceed US$34B by 2016.
Other 2014 Company Developments
In response to the double digit market demand growth for astaxanthin, the Company has entered into a joint venture to complete the development of a low cost natural astaxanthin product platform by mid 2014. Plans are to introduce this specialty natural astaxanthin product to potentially both the human and aquaculture markets after obtaining GRAS certification in late 2014.
The Company also has plans to demonstrate its natural algae based Hi EPA Omega 3 oil production platform in late 2014.
To access S4CO2's conference call, please dial 647-426-1845 or 1-866-782-8903. Pre-registration will be available 15 minutes prior to the call. A playback will be made available on the Company's website, www.s4co2.com, approximately 2 hours after the event.
The Annual Meeting of Shareholders will take place on May 28, 2014, at 10:00 a.m. (EDT), 1 First Canadian Place, 100 King Street West, Suite 1600, Toronto, Ontario, Canada.
This news release may contain forward-looking statements that are based on Solutions4CO2's expectations, estimates and projections regarding its business and the economic environment in which it operates. These statements are not guarantees of future performance and involve risks and uncertainties that are difficult to control or predict. Therefore, actual outcomes and results may differ materially from those expressed in these forward-looking statements and readers should not place undue reliance on such statements. Statements speak only as of the date on which they are made, and the Company undertakes no obligation to update them publicly to reflect new information or the occurrence of future events or circumstances, unless otherwise required to do so by law.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.